Correction to: GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Excerpt

Following publication of the original article [1], based on the authors review, the GLP1 receptor agonists in type 2 diabetes published in Cardiovascular Diabetology, a meta-analysis of GLP-1 and non-GLP-1 based therapies was performed on cardiovascular outcomes. Unfortunately, as the authors later realized, there was an error in the equation used to calculate the relative risks. Instead of subtracting the number of events from the total number of patients in the sample, these values were added which generated a similar increase in all studies. They reframed the analyzes and found small differences, which were relatively proportional to each study. There was no change in the significance of the analyzes; i.e. all data that were initially statistically significant remained significant and vice versa. The changes have been corrected in the new figures (Figs. 1, 2, Additional file 1) presented below. There was no compromise of any of the conclusions of the text and, therefore, no change was made in the manuscript.

…